Diabetes Mellitus (DM) is a chronic metabolic disease 
with complicated complex pathogenesis. Frequency of 
newly DM arises worldwide and associated with steadily 
increased morbidity and mortality due to DM-related 
complications. The incretin-based drugs are posed as 
remedies modulated effects of natural incretin hormones: 
GLP-1 (glucagon-like peptide 1), GIP (glucose-dependent 
insulinotropic peptide) and dipeptidyl peptidase enzyme 4 
(DPP4). At the beginning of the era of the incretin-based 
therapy the treatment of T2DM with GLP-1 analogs and 
DPP-4 inhibitors was introduced. In fact, incretin-based 
drug exposure was associated with clinically significant 
cardiovascular protection. However, it is not known 
whether all GLP-1 analogs and DPP-4 inhibitors are 
similar in their capacities to improve cardiovascular 
outcomes or not that is required a continuous studies in 
this direction.